

MULTIPLE SCLEROSIS AND NEUROCHEMICAL DISTURBANCES

Vladimir V. Markelov¹, Maxim V. Trushin²

ABSTRACT

The data presented in this manuscript suggest a pivotal role of the central nervous system (CNS) in the regulation of immune status. We describe here that some neurochemical disturbances may provoke development of various diseases including multiple sclerosis. Some theoretic and practical backgrounds, how to improve the multiple sclerosis sufferers and patients with other autoimmune disorders, are also given.

KEY WORDS: Multiple sclerosis, Neurotransmitters, Tryptophan, Immunomodulation.

Pak J Med Sci January - March 2007 Vol. 23 No. 1 145-149

INTRODUCTION

A bulk of studies devoted to multiple sclerosis (MS) is concentrated on therapy of the disease while studies on the MS pathogenesis are not so common. Risk factors include presence of various microorganisms (human herpesvirus 1 and 6 (HHV-1 and 6) and Epstein-Barr virus (EBV), papovavirus, Semliki Forest virus, Visna virus, varicella zoster virus, *Chlamydia pneumoniae*, some mycoplasmas). These are associated with development of MS and its animal analogs.¹⁻¹² In this situation, it is clear that Koch's paradigm "one organism, one disease" cannot be applied to such inscrutable disease like MS. It is very speculative to associate any disease with any microorganism until the whole population is not tested on the carriage of the same microbe. Epidemiologists

understand that it is a very difficult task. Unfortunately, the similar situation is observed in the MS genetics: at least 32 alleles of the major histocompatibility complex (MHC) are associated with the MS development.^{13, 14}

In our view, the most logic are concepts that connect the MS pathogenesis with the dialogue disturbance between the nervous and immune systems, particularly due to imbalance of neurotransmitters. In this manuscript we have attempted to point out some issues associated with this problem.

THE ROLE OF THE NEUROTRANSMITTER IMBALANCE IN MS AND SOME OTHER DISEASES

It is known that imbalance of neurotransmitters is the obligate condition in the MS patients as well as in people with other somatic and psychiatric disorders. Moreover, some research groups showed evidently that reversibility of normal signalization within the CNS might result in normalization of functioning of various organs and systems.¹⁵

Currently, neurological manifestations of MS are generally associated with the axon demyelination, which is considered as an examination criterion.¹⁶ However, clinical data suggest that a strong correlation between brain lesions and clinical presentation is absent. For example, as far back as late sixties researchers

1. Dr. Vladimir V. Markelov
Kazan Municipal Rehabilitation Medical Health Center
"Sanatorium Krutushka",
P.O. Box: 420130,
Kazan, - Russia.
2. Dr. Maxim V. Trushin
Kazan Institute of Biochemistry and Biophysics,
P.O. Box: 30,
Kazan - 420111, Russia.

Correspondence:

Dr. Maxim V. Trushin
E-Mail: mtrushin@mail.ru

* Received for Publication: March 29, 2006

* Accepted: June 21, 2006

showed that the vision recovery after the optic neuritis episode cannot be explained by remyelination.¹⁷ Moreover, it is known that sometime people with intensive demyelination events may have no neurological deficit.¹⁸ Also, brain lesions and the spinal cord lesions may be observed accidentally in people long before development of the first clinical signs of MS.¹⁹⁻²² The accumulated data suggest that the MS challenges cannot be considered as the direct manifestation of demyelination and that other possible factors, particularly imbalance of neurotransmitters, should be taken into account.

About thirty years ago, the level of 5-hydroxyindoleacetic acid (5-HIAA) was shown to be decreased in the cerebral spinal fluid of patients with MS.^{23,24} Additionally, the level of the above-mentioned metabolite of serotonin was more decreased in the most severely disabled MS patients.²⁵ So, the available data confirm a correlation between the level of cerebral serotonin and the disease course.

Since the beginning of sixties of the last century, intensive investigations of neurotransmitters and their metabolites were carried out in the Institute of Experimental Medicine (Caracas, Venezuela). Over 30000 healthy and diseased individuals were analyzed and some general conclusions were made. In particular, the investigators showed that patients with Th-1 immune profile (increased cellular immunity) display neurochemical features similar to those observed in major depression.¹⁵ Namely, in patients with MS, Grave's ophthalmopathy, Crohn's disease, rheumatic arthritis, psoriasis and many others, a similar neurochemical disturbances are observed: increased norepinephrine to epinephrine ratio plus decreased level of tryptophan in the blood plasma. Alternatively, in Th-2 diseases (increased humoral immunity) – myasthenia, thrombocytopenic purpura, hemolytic anemia and others – the opposite neurochemical defects are detected (profile of maladaptation to stress).¹⁵ Numerous studies by these authors have demonstrated that management of the observed neu-

rotransmitter imbalance may result in improvement of patients. Moreover, one therapeutic modality may work efficiently in patients with different disorders (Th-1 or Th-2 diseases).²⁶⁻³⁰

It should be noted here that many studies have confirmed an association between activity of immune and nervous systems.^{31,32} Immunological changes observed in the MS patients are similar to those detected in the major depressed patients.³³ It is also known that depletion of the serotonin neurotransmission may be mediated by activation of indoleamine-2,3-dioxygenase (IDO) by inflammatory cytokines.³³ Some researchers showed that the tryptophan derivatives (3-hydroxy-kynurenine (3OH-KYN) and quinolinic acid (QUIN) arisen in the kynurenine cycle have neurotoxic effect.^{34,35} Increased level of the above-mentioned metabolites is detected in neurodegenerative diseases and major depression.³⁴⁻³⁶ In turn, 3OH-KYN is able to induce the reactive oxygen species formation whose cytopathogenic effect is some well documented.³⁷ Thus, the accumulated scientific data suggest neurochemical disturbances including psychosomatic disorder are important in any neurological disease as reported by investigators.¹⁵ Therefore, prescription of some appropriate neurotrophic drugs which are able to restore neurotransmitter balance may be useful in many autoimmune diseases including MS.

SOME STEPS IN THE MS NEUROIMMUNOMODULATION

According to some authors¹⁵ enhancement of the central serotonin neurotransmission is an important step. The simplest way to increase serotonin neurotransmission is administration of the serotonin precursors like L-tryptophan and 5-hydroxytryptophan (5-HTP); the second might be synthesized in the human organism from the former. However, 5-HTP (a commercial product produced from the seeds of the African plant *Griffonia simplicifolia*) became the most popular and is used in clinical practice since the last seventies.³⁸ Efficacy of 5-HTP was confirmed in fibromyalgia,

insomnia, chronic headaches and some other pathology.³⁹ This substance crosses the blood-brain barrier without difficulties, and increases significantly the serotonin synthesis in the CNS.⁴⁰ Many factors (vitamines and minerals) may enhance this process. We have to note here that glucocorticoids frequently used for treatment of MS are able to induce IDO (an enzyme participating in the tryptophan catabolism) a fact that is known since 1980s.⁴¹

In 1987, the selective serotonin reuptake inhibitors (SSRI) were introduced into clinical practice. Initially, this type of antidepressants were used exclusively in psychiatric practice. However, during the last decade, some immunological activities of these drugs were described. At present, it is known that SSRI can cause significant decrease in synthesis of inflammatory cytokines and increase in the production of anti-inflammatory ones⁴²⁻⁴⁵ as well as mediate reduction of the interferon- α to interleukin 10 (INF- α /IL-10) ratio whose importance for T-cell activation was shown previously.⁴⁶

The presence of the increased levels of inflammatory cytokines in the MS patients was confirmed by many studies.⁴⁷⁻⁴⁹ Therefore, we consider that application of SSRI and other serotonin promoting substances with the immune downregulation properties is reasonable. Moreover, there were some positive results: administration of L-tryptophan to the MS patients resulted in improvement of autonomic, motor and sensory functions.⁵⁰ Expediency of the SSRI administration in the MS patients is currently under discussion.⁵¹ This type of antidepressant was shown to have anti-inflammatory and anti-asthenia^{52,53} besides having analgesic action^{54,55} which is very important for the MS sufferers.

CONCLUSIONS

The presented material shows an important role of interaction between the CNS and immune system.^{15,56,57} A vast experience obtained in the Institute of Experimental Medicine (Caracas, Venezuela) confirms the possibility to manage some autoimmune diseases with-

out development of relapse during a long time.^{15,26-30} In addition, application of some physiotherapeutic procedures with the prior proserotonergic therapy contributes to general improvement and long-term remission in the MS patients.⁵⁸⁻⁶⁰ We hope that neurologists engaged in the MS study will find this information useful.

REFERENCES

1. Johnson RT. The virology of demyelinating diseases. *Ann Neurol* 1994;36 (Suppl): S54-60
2. Soldan SS, Jacobson S. Role of viruses in etiology and pathogenesis of multiple sclerosis. *Adv Virus Res* 2001;56:517-55.
3. Sibley WA, Bamford CR, Clark K. Clinical viral infections & multiple sclerosis. *Lancet* 1985;1:1313-15.
4. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. *Cell* 1993;72:551-60.
5. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. *Proc Natl Acad Sci USA* 1995;92:7440-4.
6. Moore FG, Wolfson C. Human herpes virus 6 and multiple sclerosis. *Acta Neurol Scand* 2002;106:63-83.
7. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. *Ann Neurol* 2000;47:306-13.
8. Wandinger KP, Jabs W, Siekhaus A, Bubel S, Trillenberger P. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. *Neurology* 2000;55:178-84.
9. Martyn CN, Cruddas M, Compston DA. Symptomatic Epstein-Barr virus infection and multiple sclerosis. *J Neurol* 1993; *Neurosurg Psychiatry* 56:167-8.
10. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. *Neurology* 1998;50:571-2.
11. Sriram S, Stratton CW, Yao S, Tharp A, Ding L. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. *Ann Neurol* 1999;46:6-14.
12. Maida E. Immunological reactions against Mycoplasma pneumoniae in multiple sclerosis: preliminary findings. *J Neurol* 1983;229:103-11.
13. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. *Lancet Neurol* 2004;3:104-10.
14. Haines JL, Bradford Y, Garcia ME, Reed AD, Neumeister E. Multiple susceptibility loci for multiple sclerosis. *Hum Mol Genet* 2002;11:2251-6.
15. Lechin F, van der Dijs B, Lechin ME. Neurocircuitry and Neuroautonomic Disorders: Reviews and Therapeutic Strategies. Basel, Karger 2002.

16. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. *Curr Opin Neurol* 1999;12:295-302.
17. Haymaker W. Bing's local diagnosis in neurological diseases. Saint Louis. The C.V. Mosby Company, 1969.
18. Sandyk R. Demyelination as an epiphenomenon in multiple sclerosis. *Int J Neurosci* 1993;72:141-8.
19. Russel DS. Trauma and multiple sclerosis. *Lancet* 1964;1:978.
20. Ghatak NR, Hirano A, Lijtmaer H, Zimmerman HM. Asymptomatic demyelinated plaque in the spinal cord. *Arch Neurol* 1974;30:484-6.
21. Phadke JG, Best PV. A typical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necropsy. *J Neurol Neurosurg Psychiatry* 1983;46:414-20.
22. Lynch SG, Rose JW, Smoker W, Petajan JH. MRI in familial multiple sclerosis. *Neurology* 1990;40:900-3.
23. Davidson D, Pullar IA, Mawdsley C, Kinloch N, Yates CM. Monoamine metabolites in cerebrospinal fluid in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 1977;40:741-5.
24. Johansson B, Ross BE. 5-hydroxyindoleacetic acid and homovanillic acid in CSF of patients with neurological disease. *Eur Neurol* 1977;11:37-45.
25. Sonnien V, Riekkinen P, Rinne UK. Acid monoamine metabolites in cerebrospinal fluid in multiple sclerosis. *Neurology* 1973;23:760-3.
26. Lechin F, van der Dijs B. Neuropharmacological therapy of carcinoid syndrome. *Neuroendocrinology* 2005;81:137-8.
27. Lechin F, van der Dijs B, Orozco B, Hernandez-Adrian G, Rodriguez S, Baez S. Similar autonomic nervous system disorders underlying cystic fibrosis and pancreatic cysts allowed common neuropharmacological therapy: Report of four cases. *J Appl Res* 2005;5:299-304.
28. Lechin F, van der Dijs B, Orozco B, Rodriguez S, Baez S. Neuropharmacological therapy of polycythemia vera: roles of circulating catecholamines and serotonin. *Thromb Hemost* 2005;93:175-7.
29. Lechin F, van der Dijs B, Lechin AE. Treatment of bronchial asthma with tianeptine. *Methods Find Exp Clin Pharmacol* 2004;26:697-701.
30. Lechin F, van der Dijs B, Orozco B, Jahn E, Rodriguez S, Baez S. Neuropharmacological treatment of refractory idiopathic thrombocytopenic purpura: roles of circulating catecholamines and serotonin. *Thromb Haemost* 2004;91:1254-6.
31. Blalock JE. The syntax of immune-neuroendocrine communication. *Immunol Today* 1994;15:504-11.
32. Savino W, Arzt E, Dardenne M. Immunoneuroendocrine connectivity: the paradigm of the thymus-hypothalamus-pituitary axis. *Neuroimmunomodulation* 1999;6:126-36.
33. Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. *Prog Neuro-Psychopharmacol Biol Psychiatry* 2005;29:201-17.
34. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpe S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. *Life Sci* 2002;71:1837-48.
35. Wichers M, Maes M. The role of indoleamine 2,3 dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. *J Psychiatry Neurosci* 2004;29:11-17.
36. Mangoni A. The kynurenine shunt and depression. *Adv Biochem Psychopharmacol* 1974;11:293-8.
37. Hendriks JJA, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration *Brain Res Rev* 2005;48:185-95.
38. Turner EH, Blackwell AD. 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. *Med Hypoth* 2005;65:138-44.
39. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. *Altern Med Rev* 1998;3:271-80.
40. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. *Pharmacol Ther* 2005;109:325-38.
41. Salter M, Pogson CI. The role of tryptophan 2, 3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. *Biochem J* 1985;29:499-504.
42. Kubera M, Lin A, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. *J Clin Psychopharmacol* 2001;21:199-206.
43. Maes M. The immunoregulatory effects of antidepressants. *Hum Psychopharmacol* 2001;16:95-103.
44. Maes M, Song C, Lin A-H, Bonaccorso S, Kenis G. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. *Neuropsychopharmacology* 1999;20:370-9.
45. Kubera M, Kenis G, Bosmans E, Scharpe S, Maes M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. *Neuropsychopharmacology* 2000;23:89-98.
46. Katsikis PD, Cohen SB, Londei M, Feldman M. Are CD4+ Th1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to INF-gamma or IL-2 determines their function. *Int Immunol* 1995;7:1287-94.
47. Carrieri PB, Provitera V, De Rosa T, Tartaglia G, Gorga F, Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical of IRS activation, such as T cell activation (increased activity. *Immunopharmacol Immunotoxicol* 1998;20:373-82.

48. Hautecoeur P, Forzy G, Gallois P, Demirbilek V, Feugas O. Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. *Acta Neurol Belg* 1997;97:240-3.
49. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. *Eur Neuropsychopharmacol* 2001;11:203-8.
50. Hyypya MT, Jolma T, Riekkinen P, Rinne UK. Effects of L-tryptophan on central indoleamine metabolism and short-lasting neurologic disturbances in multiple sclerosis. *J Neural Transm* 1975;37:297-304.
51. Joffe RT. Depression and multiple sclerosis: a potential way to understand the biology of major depressive illness *J Psychiatry Neurosci* 2005;30:9-10.
52. Mohr DC, Goodkin DE, Islar J, Hauser BSL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific Th1 responses in multiple sclerosis. *Arch Neurol* 2001;58:1081-6.
53. Mohr DC, Hart SL, Golberg A. Effects of treatment for depression on fatigue in multiple sclerosis. *Psychosom Med* 2003;65:542-7.
54. Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. *J Gen Intern Med* 1997;12:384-9.
55. Duman EN, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N. Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. *J Pharmacol Sci* 2004;94:161-5.
56. Sandyk R. Serotonergic neuronal atrophy with synaptic inactivation, not axonal degeneration, are the main hallmarks of multiple sclerosis. *Int J Neurosci* 1998;95:133-40.
57. Sandyk R. Tryptophan availability and the susceptibility to stress in multiple sclerosis: a hypothesis. *Int J Neurosci* 1996;86:47-53.
58. Sandyk R. Progressive cognitive improvement in multiple sclerosis from treatment with electromagnetic fields. *Int J Neurosci* 1997;89:29-38.
59. Sandyk R. Successful treatment of multiple sclerosis with magnetic fields. *Int J Neurosci* 1992;66:237-50.
60. Sandyk R. Rapid normalization of visual evoked potential by picotesla range magnetic fields in chronic progressive multiple sclerosis. *Int J Neurosci* 1993;77:243-59.